Case of erlotinib‐induced photosensitivity

Fukai, Tatsuo; Hasegawa, Toshio; Nagata, Ayako; Matsumura, Maiko; Kudo, Yukako; Shiraishi, Eriko; Kamiya, Yuki; Hirasawa, Yusuke; Ikeda, Shigaku

doi:10.1111/1346-8138.12476

Cited by 6 publications

(1 citation statement)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among new targeted therapies, photosensitivity has been described with imatinib (several cases of pseudoporphyria) 51 , sunitinib (pseudoporphyria) 112 , brigatinib (sunburn like reaction) 39 , erlotinib 113 (also with acne-like reactions predominating in sun-exposed areas), crisotinib 5 , pazopanib (phototoxicity and hyperpigmentation) 114 , vandetanib (phototoxic and several photoallergic reactions with erythema multiforme-like aspects, confirmed by photopatch tests) 61,114 , and, particularly, with vemurafenib. When used as a single therapy in metastatic melanoma up to two thirds of patients develop vemurafenib photosensitivity in the spectrum of UVA presenting as immediate burning and painful sensation and a sharply demarcated erythema and edema that appear still during UV irradiation, resembling solar urticaria, but erythema and edema persist for a few days 77 .…”

Section: Anticancer Drugsmentioning

confidence: 99%

Drug-induced photosensitivity

Gouveia

Gameiro

Coutinho

et al. 2023

PJDV

View full text Add to dashboard Cite

Drug photosensitivity is a relatively frequent adverse event, although not always recognized due to its clinical polymorphism and difficulties in performing tests to prove drug causality.The aim of this report is to review the mechanisms of photosensitivity related with topical and systemic drugs (phototoxicity, photoallergy, autoimmunity, and enhanced photocarcinogenesis), the main acute and delayed clinical manifestations (acute sunburn or eczema, pseudoporphyria, photo-onycholysis, dyschromia, telangiectasia, subacute lupus erythematosus, pre-cancerous lesions, and cutaneous neoplasia), the main culprits [non-steroidal anti-inflammatory drugs (NSAIDs), antimicrobials, like fluoroquinolones and tetracyclines, psychotropic, anticancer, and cardiovascular drugs] and the most adequate diagnostic procedures (photopatch and drug photoprovocation tests).

show abstract